NEWS & INSIGHTS

20 July 2021

iOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin Inhibitor IOA-289

7 July 2021

ONCORESPONSE APPOINTS SEAN McCARTHY TO BOARD OF DIRECTORS

15 June 2021

Personal Genome Diagnostics Enters Collaborative Partnership with Clinical Molecular Diagnostics Laboratory of Major University Health System

15 June 2021

UTILITY Therapeutics Preparing NDA Submission

10 June 2021

Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders

19 May 2021

Fore Biotherapeutics Strengthens Leadership Team with Executive and Board Appointments

17 May 2021

Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement

11 May 2021

OncoResponse Appoints Chris Russell as Chief Financial Officer

11 May 2021

UTILITY Therapeutics Announces Scientific Advisory Board

10 May 2021

Fore Biotherapeutics Opens U.S. Headquarters in Philadelphia’s Biotech Hub

3 May 2021

Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress

13 April 2021

Start-up GreenBone closes a EUR10m Series B round

31 March 2021

OncoResponse Raises $40.6 Million Series C Financing

24 March 2021

3B FUTURE HEALTH GP S.A.R.L. ANNOUNCES THE LAUNCH OF 3B FUTURE HEALTH FUND II

18 March 2021

Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock

9 March 2021

NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline

24 February 2021

NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board

4 February 2021

Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium

21 September 2020

Novellus Closes $57M Series C Financing

10 September 2020

Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program

21 July 2020

Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing

14 July 2020

3B Future Health Fund Announces New Investment in iOnctura

8 June 2020

QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test

14 April 2020

OncoResponse Appoints Robert Lechleider, MD as Chief Medical Officer; Promotes Kamal Puri, PhD to Chief Scientific Officer

31 January 2020

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

30 January 2020

The GreenBone bone substitute achieves CE certification

15 July 2019

Helsinn Investment Fund Announces First Exit

19 March 2019

Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced

19 February 2019

Helsinn Investment Fund Invests €1 Million in Gain Therapeutics

23 January 2019

QuantuMDx & St George’s begin field study: cervical cancer screening test

30 April 2018

NovellusDx Announces It Has Completed an Equity Financing of $6 Million

28 March 2018

Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced

14 March 2018

On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

30 January 2018

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

5 September 2017

AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round

16 June 2017

Helsinn Investment Fund Leads the Financial Round in GreenBone

8 May 2017

Helsinn Investment Fund Invests in Aadi Bioscience

10 October 2016

Helsinn Group Introduces Helsinn Investment Fund

10 October 2016

Helsinn Investment Fund Invests £2.0 Million in QuantuMDx

10 October 2016

Helsinn Investment Fund to Invest $3.5 Million in OncoResponse

8 August 2016

Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialisation of Pracinostat for the Treatment of Acute Myeloid Leukaemia and Other Haematologic Diseases